Exhibit 99.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
Included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is a poster titled “Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Participants with Developmental and Epileptic Encephalopathies: Results of the Phase 1b/2a PACIFIC Study” (the “Poster”). Longboard Pharmaceuticals, Inc. (the “Company”) is scheduled to present the Poster at the 76th Annual Meeting of the American Academy of Neurology on April 15, 2024. The Company also expects to use the contents of the Poster in various meetings and presentations with securities analysts, investors and others beginning on April 15, 2024.
The Company also plans to make the Poster available on its website (http://www.longboardpharma.com), on the page titled “Our Approach,” under the heading “Publications.”
Information contained in, or that can be accessed through, the Company’s website is not incorporated by reference into this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
|
|
Exhibit No. |
Description |
99.1 |
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Longboard Pharmaceuticals, Inc. |
|
|
|
|
|
Date: April 15, 2024 |
|
By: |
/s/ Kevin R. Lind |
|
|
|
Kevin R. Lind |
|
|
|
President and Chief Executive Officer |
Exhibit 99.1
XZ4&EX>6#HS!R5+Z
ML*_5[VFU5:M_MC3O:35U:9XL1<5_YH 6P)VG#G">=,W3'IAWN**:0(M.)3U3
M"-\(8"<]N'G\R J2GT!X(0JJ5, 1^5"&8!95*^]138(9S@#$4?V-%4-S-@W*
M,>!.'W;].ASX"(,:3R5,\=%2T7.]6N!,57:.+\C